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Abstract
Background: Vasopressor therapy in patients with septic shock can lead to
harmful effects.
Objective: To describe vasopressor titration in patients with septic shock.
Methods: Single-center descriptive study of 60 intensive care unit (ICU) patients
to calculate rates for events of failure to titrate, incorrect titration, and correct
titration in 15- minute intervals for the duration of vasopressor therapy. Total
hospital and ICU days, mortality rate, vasopressor dose and time, and the impact
of hydrocortisone on vasopressor use were examined.
Results: During the total vasopressor infusion time of 2598 hours, 5395 failure to
titrate events were noted. There were 316 incorrect titrations, 704 correct
titrations, and 3977 time intervals when titration was not indicated. Converting the
aggregate titration opportunities to an hourly rate, and based on documentation
of mean arterial blood pressure at 15-minute intervals, the failure-to-titrate hourly
rate was 50%, the incorrect- titration rate was 2%, and the correct-titration hourly
rate was 48% (correct titration and titration not indicated). Patients with higher
acuity score were more likely to receive corticosteroids than those with lower
acuity score. When controlling for acuity of illness with APACHE II or SOFA
iv

scores, Cox regression showed no meaningful difference (p =.18 for APACHE II
and p = .31 for SOFA) in time on vasopressors between patients receiving and
those not receiving corticosteroids.
Conclusion: Failure-to-titrate vasopressor events are high in MICU patients with
septic shock.
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Summary of the Study
This dissertation has three major components. The proposal
encompasses work that was approved by the Dissertation Committee during the
proposal defense held September 19, 2016. The manuscript, “Vasopressor
Titration in Medical Intensive Care Patients with Septic Shock: A Descriptive
Study,” contains the findings. The appendices include the Institutional Review
Board (IRB) approvals (Appendix A), the study Data Collection Protocol
(Appendix B), one publication related to the study (Appendix C), data analysis
tables not reported in the manuscript (Appendix D), and the student's curriculum
vitae (Appendix E).
The proposed study design was a prospective historical control
intervention study of narrowed monitor alarm parameters to decrease
vasopressor usage in intensive care unit (ICU) patients with septic shock. The
planned study addressed the following specific aims to determine: (1) if narrowed
mean arterial pressure (MAP) monitor alarm parameters decreases vasopressor
usage, and (2) differences in outcome measures between patients with narrowed
and default MAP monitor alarm parameters.
At the proposal defense, the Dissertation Committee members
recommended: (1) addressing the effect size and rationale for parameters used
in the sample size estimation; (2) standardizing corticosteroid use, oversampling
the historical control group to estimate percentage of septic shock patients who
receive steroids, and comparing groups of patients with and without
corticosteroid treatment; (3) replacing 28-day all-cause mortality as an outcome
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measure with ICU and hospital all-cause mortality; (4) correlating mean
noninvasive blood pressure (NIBP) with arterial catheter MAP as part of the study
protocol; (5) adding data and/or supporting evidence for the default alarm use;
(6) clarifying all alarms that may be activated during the project and classifying as
critical vs. moderate; (7) strengthening the justification for not personalizing the
MAP alarms by patient; (8) incorporating decisions for protocol violations into the
study protocol; and (9) developing a check list for screening patients for study
participation.
Due to misunderstanding of the study objectives, a major delay occurred
with the Houston Methodist Hospital IRB approval. After the student, dissertation
chair, and IRB staff met on three separate occasions, the study was approved by
the IRB and subsequently by the University of Texas Health Science Center
Committee for the Protection of Human Subjects via the State of Texas Master
IRB Reciprocity Agreement.
Enrollment posed a challenge. Initially, low enrollment was due to a
change in practice to avoid the use of arterial catheters, an inclusion criterion for
study participation. The IRB approved a protocol change to remove the presence
of an indwelling arterial catheter as an inclusion criterion. Enrollment continued to
be low, averaging 7 patients per month; it was determined that approximately 2
years of data collection would be required to meet the proposed sample size.
Concomitantly, the U.S. Food and Drug administration approved the use of
Angiotensin II for distributive shock. The use of this medication was noted to be a
confounding variable for this study. Therefore, the Dissertation Committee met
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again on September 7, 2018 and agreed to stop data collection on December 31,
2018 or administration of Angiotensin II in the ICU, whichever occurred first. The
Committee approved changes in the study objective and methods at this
meeting.
The study varied from the proposal in the following ways. Study design
was changed from a historical control intervention study to a descriptive analysis
of the current practice of nurse titration of vasopressors. Analysis of the impact of
hydrocortisone on vasopressor use was added. Although not included in the
manuscript, linear regression analysis was performed to assess for a meaningful
difference in vasopressor dose between corticosteroid groups and is presented in
Appendix D.
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NARROWED MONITOR ALARM PARAMETERS TO DECREASE
VASOPRESSOR USAGE IN SEPTIC SHOCK: AN HISTORICAL CONTROL
INTERVENTION STUDY
Introduction
Sepsis is the leading cause of death in non-coronary intensive care units
(ICUs) in the United States (Surviving Sepsis Campaign, 2012). Over 750,000
cases of sepsis occur annually and it is the 11th leading cause of death in the
United States (Centers for Disease Control and Prevention, 2012). Septic shock
arises from sepsis and is defined as the presence of an infection that causes
organ dysfunction, hemodynamic compromise, and metabolic abnormalities that
are severe enough to increase mortality (Singer et al., 2016). Septic shock has a
mortality rate of up to 70% in the ICU setting (Surviving Sepsis Campaign, 2012).
Causes of death are multifactorial, but there is strong evidence to suggest that
the use of vasopressors contributes to overall mortality and such complications
as myocardial, renal, and splanchnic ischemia (Nygren et al., 2006; Micek et al.,
2007). Despite the serious complications associated with these drugs,
vasopressors are used to treat septic shock-induced hypotension in order to
maintain adequate blood pressure and tissue perfusion after fluid resuscitation
efforts have failed (Surviving Sepsis Campaign, 2012). The use of these drugs
continues until endogenous catecholamine stores are repleted and the patient
reaches an optimal mean arterial pressure (MAP) (Obritsch et al., 2004).
Duration of vasopressor therapy can vary from several hours to weeks
(Micek et al., 2007). Early therapy is focused on maintaining an optimal MAP to
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ensure autoregulation and perfusion of tissues. This may require upward and
downward titration of vasopressors to reach a target MAP. Once the patient
maintains or exceeds the target MAP, interventions are initiated to wean
vasopressor therapy with discontinuance as the goal. Providers typically
establish vasopressor titration parameters (e.g., maintain MAP of 60-65 mmHg),
but the actual process of titrating vasopressors is based on nursing discretion,
and often includes erratic changes in MAP (Merouani et al., 2008). MAP monitor
alarms are used to guide vasopressor titration to ensure the patient maintains
adequate perfusion, and the MAP does not deviate widely from the target value.
Nurses rarely individualize alarm parameters based on patient response; instead,
they maintain parameters at the default setting unless the patient has clearly
aberrant MAP values.
In the proposed study, MAP monitor alarm limits will be narrowed to
prompt the nurse to more frequently titrate vasopressor dosage and,
consequently, more rapidly discontinue use of vasopressor therapy. The study
intervention is narrowed MAP alarm limits of the bedside monitor to a range of
55-70 mmHg instead of the default range of 55-110 mmHg. It is unknown if
narrowed alarm limits will significantly impact patient outcomes. The central
hypothesis is that the institution of narrowed alarm limits will decrease
vasopressor usage and improve measures of patient outcome. This study will not
alter MAP treatment goals for patients with septic shock. Indeed, the intervention
is expected to facilitate attainment of treatment goals more effectively, safely,
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and rapidly than the current practice of using default MAP monitor alarm settings
to guide vasopressor titration.
The specific aims are to determine in ICU patients with septic shock:
Aim 1: If narrowed MAP monitor alarm parameters decreases vasopressor
usage, and
Hypothesis 1: Compared with default alarm parameters, narrowed MAP monitor
alarm parameters will decrease total vasopressor dosage (measured in mcg/min)
and vasopressor usage time (measured in hours).
Aim 2: Differences in outcome measures between patients with narrowed and
default MAP monitor alarm parameters.
Hypothesis 2: The use of narrowed MAP monitor alarm parameters will decrease
(a) ICU length of stay (measured in days), (b) hospital length of stay (measured
in days), and (c) 28-day all-cause mortality.
The experimental group will have narrowed monitor alarm parameters and
will be compared to the control group that will have alarm parameters at the
default setting, per the current standard of practice. The experimental group is
expected to demonstrate less vasopressor dosage and usage time, shorter ICU
and hospital lengths of stay, and lower 28-day all-cause mortality than the control
group.
Significance
A paucity of research has been published on vasopressor titration and
utilization of alarm parameters to improve patient outcomes. Merouani et al.
(2008) found a significant reduction in 28-day mortality rates when using closed
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loop control based on fuzzy logic to decrease norepinephrine dosage in 39
patients demonstrating septic shock. However, the small sample size and limited
availability of this technology decreased generalizability of the study findings. Biot
et al. (2003) analyzed 103 ICU patients to evaluate the necessity of systematic
activation of alarms for non-invasive blood pressures. They noted that systematic
activation of auditory alarms for non-invasive blood pressure monitoring in stable
ICU patients is unnecessary for safety, and proposed a protocol of activationdeactivation of auditory alarms for noninvasive MAP monitoring. Patients with
septic shock are unstable and have invasive, direct (arterial catheter) measures
of MAP, limiting the application of Biot et al’s findings to ICU patients with septic
shock.
Most of the research on monitor alarms has addressed reduction of false
monitor alarms in the ICU setting. Chambrin (2001) suggested that the best
strategy is to tailor the monitor alarms to each patient by setting the alarm to
detect events that are clinically relevant for the patient – an approach consistent
with the premise of the proposed study. This study will not tailor the alarms to
each patient, but instead tailor the alarms to a specific disease process (septic
shock). Future research can be performed with patient-specific monitor alarms
based on the findings of this study.
Several organizations, including the American Association of Critical Care
Nurses (AACN) and the Health Technology Foundation, recommend staff nurses
institute patient-specific or disease-specific alarm parameters to not only
decrease the incidence of false monitor alarms but also improve patient
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outcomes (AACN, 2011; Health Technology Foundation, 2011). However, there
have been no published studies to indicate the benefits of such approaches; a
knowledge gap exists as to whether the initiation of narrowed alarm limits
significantly impacts patient outcomes.
Because vasopressor use contributes to overall mortality and organ
ischemia of ICU patients (Nygren et al., 2006; Micek et al., 2007), rapid titration
of vasopressors is expected to decrease harm to the patient. Currently,
vasopressor titration guidelines do not exist, and the standard of practice is to
adjust vasopressor dosage based on nursing intuition and experience.
Conceptually, reminding nurses to titrate, via auditory and visual monitor
alarms, should promote faster downward titration (weaning) of vasopressors and
improve patient outcomes. A conceptual framework for nurse decision-making is
shown in Figure 1. The first step in this decision process is recognition of an
aberrant MAP value; aberrancy depends on the patient, the environment, and the
underlying problem facing the patient. Knowledge, experience and skill of the
bedside nurse are key features that aid in recognition. Once the nurse
recognizes a problem, an appraisal is made as to whether a change in
vasopressor therapy is indicated. When a change is made, the nurse rerevaluates this change several minutes later. Additional manipulations in therapy
may be required to maintain MAP at the target level. The decision-making
process uses a circular thinking pathway because several titration attempts may
be required before the desired MAP is attained. The process is iterative until the
patient maintains the target MAP value without vasopressor (i.e., weaned). The
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premise of the proposed study is that narrowed MAP monitor alarm parameters
will accelerate nurse titration decision-making, leading to less vasopressor
dosage and usage time and improved patient outcomes, compared with use of
default MAP monitor alarm limits.

Figure 1. Nurse Titration Decision Making Conceptual Framework

The septic shock ICU population was selected to trial the intervention
because this population develops hypotension secondary to endogenous nitric
oxide release (Martin, Cheek, & Morris, 2015). The nitric oxide release is
secondary to endothelial damage and the release of endotoxins in the blood
stream. Treatment is first geared toward adequate fluid resuscitation and then
initiation of vasopressor therapy to improve blood pressure. Vasopressor
treatment goals for MAP in this population are provided by the Surviving Sepsis
Campaign (Dellinger et al., 2013). Effective methodologies for rapid titration of
vasopressors in the septic shock ICU population may be applicable to other
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populations such as patients with cardiogenic or neurogenic shock wherein
vasodilation is a prominent feature.
Innovation
The Surviving Sepsis Campaign provides treatment guidelines for the
management of patients with sepsis and septic shock. These guidelines
recommend the titration of vasopressor therapy to maintain a MAP of 65 mmHg
(Dellinger et al., 2013), which is the lowest perfusion pressure to maintain
adequate systemic circulation at the microvascular level (LeDoux et al., 2000;
Hamlin, Parmely, & Hanneman, 2014; Arellano & Hanneman, 2014). However,
the guidelines do not address titration methodology. Furthermore, no published
studies were located regarding testing narrowed alarm parameters to encourage
rapid titration of vasopressor therapy. The proposed study will measure the
effects of narrowed alarm parameters to stimulate rapid titration of vasopressors.
Approach
Research Design and Methods
The specific aims will be pursued with a prospective, non-randomized
controlled trial with a pre- and post- intervention study design. During phase 1
(historical control), all patients who meet the eligibility criteria will be placed in the
control group (standard practice) and will have MAP monitor alarm parameters at
the default setting of 55-110 mmHg. Data collection will commence as described
below until a total control group sample size of 64 is reached. During phase 2,
the intervention will be introduced to the entire nursing staff, and data will be
collected on 64 patients who meet the eligibility criteria. The experimental group
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(narrowed monitor alarm parameters) will have MAP alarm limits of 55 – 70
mmHg. The target MAP for vasopressor therapy will be 65 mmHg for both groups
(Dellinger et al., 2013; Surviving Sepsis Guidelines, 2012). Total vasopressor
dosage, vasopressor usage time, ICU and hospital lengths of stay, and 28-day
all-cause mortality will be compared between the experimental and control
groups. Due to the cost and logistics of revamping bedside monitors in the ICU,
blinding will not be used. Rather, the control group will be studied first. Then,
following education of ICU staff, narrowed alarm limits will be instituted and data
collected for the experimental group. Although this approach introduces possible
bias from selection, maturation, and history effects, it will prevent contamination
of the control group (Sacks, Chalmers, & Smith, 1982).
Setting and Sample
The setting will be a 24-bed medical ICU (MICU) of a 915-bed tertiary care
hospital in the Texas Medical Center. The MICU admits annually 260 adult
patients with septic shock. Norepinephrine and phenylephrine are the most
commonly used vasopressors in the MICU.
The sample will be adult ICU patients with septic shock, defined as the
presence of an infection, with end organ dysfunction and hemodynamic
compromise (Dellinger et al., 2013). Inclusion criteria are: (a) MICU patient ≥ 18
years old; (b) presence of ≥ 2 signs of Systemic Inflammatory Response
Syndrome (SIRS) (Table 1); (c) documentation of infection by positive culture,
radiographic findings consistent with infection, or a clinical syndrome associated
with a high probability of infection (Table 1); (d) vasodilatory, volume-refractory
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shock (central venous pressure [CVP] > 6 mmHg, urine output > 30 cc/hr)
necessitating administration of norepinephrine or phenylephrine for ≥ 4 hours to
maintain MAP > 60 mmHg; and (e) presence of arterial and central venous
catheters.

Table 1
Septic Shock Criteria
Infection Criteria
(At least 1)
1) Leukocytes in otherwise sterile
corporal liquid
2) Radiographic evidence of
pneumonia
3) Perforated abdominal viscus
4) Clinical syndrome associated with
infection (e.g., cholangitis)

SIRS Criteria
(At least 2)
1) Temperature > 38C or < 36C
2) RR > 20/min or PaCO2 <
32mmHg, or need for mechanical
ventilation
3) Leukocytes >12,000 k/uL or <
4,000 K/uL, or bands > 10%
4) HR > 90/min

Note. SIRS=Systemic Inflammatory Response Syndrome; RR=Respiratory
Rate; PaCO2=Partial pressure of carbon dioxide in arterial blood; HR=Heart
Rate
Exclusion criteria are: (a) possibility of other types of shock (i.e.,
hypovolemic, cardiogenic, anaphylactic, or neurogenic); (b) inadequate volume
resuscitation (Central Venous Pressure < 6 mmHg or urinary output < 30 cc/hr in
the presence of normal renal function); (c) inability to determine presence of
infectious process; and (d) pregnancy, severe head injury, and/or status post
cardiac arrest.
The independent samples t-test will be utilized to measure vasopressor
and outcome differences between the control and experimental groups. With a
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medium effect size (Cohen’s d = 0.5; Cohen, 1988), two-tailed alpha of 0.05, and
power of 80%, the minimum total sample size is 128 with a minimum sample size
per group of 64.
Recruitment and Follow-Up of Subjects
The charge nurse or the study investigator will screen all patients with a
working diagnosis of sepsis and/or shock and enroll those who meet the study
eligibility criteria. Informed consent will not be obtained, as there will be no
change in patient care or treatment; only monitoring alarm parameters will be
experimentally manipulated. Participants will be followed through hospital
discharge or death to obtain outcome data. Patients with septic shock requiring
vasopressor therapy in the ICU who are discharged within 28 days will be
followed up by telephone to obtain mortality outcome data.
Intervention
The intervention will be the institution of narrowed MAP monitor alarm
limits of 55-70 mmHg (Figure 2). The theoretical basis for this intervention is that
narrowed alarm limits will help facilitate less vasopressor dosage and duration of
vasopressor therapy than standard practice with the default alarm limits of 55 –
110 mmHg (General Electric Medical Systems Information Technologies [2009])
(Figure 3). A single auditory moderate-volume alarm and a single blue visual
screen reminder will be used for both groups.
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Figure 2. General Electric monitor graphical user interface showing experimental
MAP high (70 mmHg) and low (55 mmHg) alarm parameters. Yellow arrow points
to visual alarm activation because MAP (81 mmHg) exceeds the high alarm limit
(70 mmHg).

16

Figure 3. General Electric monitor graphical user interface showing (A) default
mean arterial pressure (MAP) high (110 mmHg) and low (55 mmHg) alarm
parameters.
The MICU charge nurses will be trained in the proper selection of patients for
the study. A log will be kept in the locked drawer of the nurse’s station listing
patients enrolled in the study, their MICU bed assignment, and date of study
enrollment and reviewed by the study coordinator daily. MICU nursing staff will
receive training and reinforcement about the process for MAP monitor alarm
parameter manipulation. The study protocol (Appendix A), adapted for historical
control or intervention group, will be available to all MICU nurses at the
centralized nursing station.
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Measurement
Biometric measurement devices such as the arterial catheter greatly
improve the monitoring of hemodynamic status and facilitate faster
discontinuance of vasopressors (Marino, 2007); blood pressure can be measured
directly with an arterial catheter, a transducer, and a physiologic monitor.
Catheters (18-gauge, radiopaque, Arrow International) are placed into the radial
and/or femoral artery in the MICU and arterial pressures are measured with a
pressure transducer (PXMK2011, Edwards Lifesciences) cabled to a bedside
physiologic monitor (Carescape, General Electric Medical Systems Information
Technologies). Validity of the MAP monitoring system has been well-established
(Pauca, Wallenhaupt, Kon, & Tucker, 1992).
The arterial line and pressure transducers are fluid-filled and provide a
direct arterial pressure waveform measurement indicative of the systolic and
diastolic pressure within the heart (Marino, 2007). The continuous pressure
waveform spectrum of systolic and diastolic readings is displayed digitally on the
monitor (Figure 4). The MAP is calculated by the physiologic monitor and is the
basis for modulation of care. Variables such as transducer location, drift,
calibration and equipment error can affect the accuracy of the MAP reading.
Calibration of the MAP monitoring system will be done every shift, following a
change in patient position/bed height, and after accessing the line to reduce the
potential for measurement error (Appendix A). The monitor numerical value for
MAP will be used to titrate vasopressors.
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Figure 4. The arterial line, fluid-filled pressure transducer, and cardiac monitor
displaying the systolic and diastolic pressure within the artery.
Vasopressor data will be collected from the electronic medical record
(EMR). The Alaris® infusion pump system (version 9, Model 8015, Cardinal
Health) provides wireless connectivity to clearly communicate critical
programming, infusion, and monitoring information; this allows for vasopressor
data to be automatically communicated to the EMR.
The severity of organ dysfunction will be assessed with the use of Acute
Physiology and Chronic Health Evaluation II (APACHE) (Knaus, Draper, Wagner
& Zimmerman, 1985) and Sequential Organ Failure Assessment (SOFA)
(Vincent, J. L., et al., 1996). Higher APACHE II and SOFA scores are associated
with increased probability of mortality. The scores grade abnormality by organ
system and the SOFA score accounts for clinical interventions. Reliability
estimates for the APACHE II and SOFA are 0.90 and 0.89, respectively, in the
adult critical care population ((Kho, McDonald, Stratford, & Cook, 2007); Arts et
al., 2005). The a priori criterion for acceptable reliability estimates for the
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proposed study is .80 (Nunnally & Bernstein, 1994). The validity of SOFA and
APACHE II as a measure of acuity and predictive mortality has been
demonstrated in the literature. The area under the receiver-operating
characteristic curve is >.80 for both scores in multiple studies (Janssens, et al.,
2000; Moreno et al, 1999; Giangiuliani, Mancini, & Gui, 1989; Capuzzo, et al.,
2000).
Data Collection
The researcher will collect the data and place it in a spreadsheet kept on
an encrypted, password-protected flash drive within a locked cabinet located at
the University of Texas Health Science Center at Houston School of Nursing.
Aim 1: Determine if narrowed MAP monitor alarm parameters decrease
vasopressor usage compared with the default MAP monitor alarm parameters.
Demographic data of age, gender, ethnicity, race, diagnoses, height and
weight will be collected from the EMR for each patient enrolled in the study.
APACHE and SOFA score data points will be collected to describe patient acuity
(Appendices B and C, respectively). Corticosteroid use also will be documented
because several systematic reviews have demonstrated an improved septic
shock reversal by utilizing low-dose hydrocortisone. (Sligl et al., 2009; Annane et
al., 2009). Total vasopressor dosage (mcg/min) and total vasopressor usage time
in hours will be determined.
Aim 2: Determine differences in outcome measures between patients with
narrowed and default MAP monitor alarm parameters.
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The source of infection will be documented from microbiology culture data
and clinical documentation. ICU and hospital lengths of stay will be calculated
from the EMR. All-cause, 28-day mortality data, starting with day one of
vasopressor infusion(s) and ending at day 28, will be collected from the EMR or
post-discharge phone calls if indicated. The same data will be collected for both
the experimental and control group patients. The primary outcome will be total
vasopressor usage time (hours). Secondary outcomes will be total vasopressor
dosage (mcg/min), ICU and hospital lengths of stay, and mortality rates.
Data Analysis
Demographic data will be analyzed with descriptive statistics appropriate
for the level of measurement and distribution of the data. The independent twosample t-test will be used to analyze the differences in vasopressor dosage and
usage time between the experimental and control groups. Poisson distribution
regression analysis (Kirkwood & Sterne, 2003) will be performed to assess the
impact of acuity (APACHE II and SOFA scores) on the total vasopressor dosage
and usage time. Further regression analysis will examine the impact of age,
corticosteroid use, and difference between the two study groups on 28-day
survival rate (alive or dead at 28 days) by Chi Square. Statistical assumptions
will be addressed. Normality will be addressed by reviewing the distribution
graphically (via histograms) and analysis of the skewness and kurtosis.
Regression linearity will be assessed with the goodness of fit test.

21
Protection of Human Subjects
Human subjects involvement and characteristics. Human subjects will
be selected from a pool of MICU patients 18 years or age or older. Patients must
meet the criteria for septic shock and require intravenous vasopressor therapy.
Sources of materials/data. The bedside monitoring system will be used
as the point of intervention. The experimental group will have MAP monitor alarm
parameters narrowed to a clinically safer range of 55-70 mmHg as opposed to
the 55-110 mmHg range that is currently used. Narrowed monitor alarm
parameters will signal the nurse to titrate the vasopressors upward or downward
to maintain the target MAP value. A single auditory moderate-volume tone and a
single blue visual screen reminder will be activated as alarms when the MAP falls
outside the specified range. The control group patients will not receive narrowed
MAP alarm limits; instead, nurses will continue with the current standard of
practice with the default alarm parameters of 55 – 110 mmHg. The EMR will be
used to collect demographic data of age, gender, ethnicity, race, diagnoses,
height, and weight; vasopressor dosage and usage time, APACHE II and SOFA
scores, infection source, corticosteroid use, ICU and hospital lengths of stay, and
survival status at 28 days.
Informed consent will not be obtained, as there is no change in usual
patient care that will place the patient or staff at significant risk.
Potential Risks. There are few risks to the human subjects from this
study. Christensen (2007) identified a correlation between higher noise levels
and increased incidence of delirium. Cvach (2012) noted that nurses often
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experience alarm fatigue. However, a closer look at that same literature
demonstrates that adjustment of monitor alarms to the patient’s specific needs is
critical in ensuring the alarms are an early warning to critical situations and less
likely to alarm erroneously. Another risk involves the breach of confidentiality.
Adequacy of Protection Against Risk
Recruitment. Recruitment of patients will be from the MICU population at
a large tertiary care center. The charge nurse or the study coordinator will select
patients who meet the eligibility criteria and place them into the study.
Protection against risks. There are few risks to the human subjects with
the experimental component of this study. Standards of care to reduce the
incidence of delirium in the ICU patient will be followed. These include
appropriate sleep wake cycle simulation, reduction of nighttime interventions, and
pharmacotherapy if indicated (Christensen, 2007). To protect the patients from
loss of confidentiality, the data will only be reviewed by the research staff and
kept secure at all times in a locked cabinet. No personal identifiers will be used in
dissemination of the findings; data will be presented in the aggregate. All
research personnel partake in extensive protected health information training
annually. In the event of a data breach, the Institutional Review Board and the
patient will be notified.
Inclusion of Women and Minorities
There are no inclusion/exclusion criteria based on sex or race. Subject
recruitment will occur at the hospital that has a patient population reflective of the
diversity of the general population of Houston.
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Abstract
Background: Vasopressor therapy in patients with septic shock can lead to
harmful effects.
Objective: To describe vasopressor titration in patients with septic shock.
Methods: Single-center descriptive study of 60 intensive care unit (ICU) patients
to calculate rates for events of failure to titrate, incorrect titration, and correct
titration in 15- minute intervals for the duration of vasopressor therapy. Total
hospital and ICU days, mortality rate, vasopressor dose and time, and the impact
of hydrocortisone on vasopressor use were examined.
Results: During the total vasopressor infusion time of 2598 hours, 5395 failure to
titrate events were noted. There were 316 incorrect titrations, 704 correct
titrations, and 3977 time intervals when titration was not indicated. Converting the
aggregate titration opportunities to an hourly rate, and based on documentation
of mean arterial blood pressure at 15-minute intervals, the failure-to-titrate hourly
rate was 50%, the incorrect- titration rate was 2%, and the correct-titration hourly
rate was 48% (correct titration and titration not indicated). Patients with higher
acuity score were more likely to receive corticosteroids than those with lower
acuity score. When controlling for acuity of illness with APACHE II or SOFA
scores, Cox regression showed no meaningful difference (p =.18 for APACHE II
and p = .31 for SOFA) in time on vasopressors between patients receiving and
those not receiving corticosteroids.
Conclusion: Failure-to-titrate vasopressor events are high in MICU patients with
septic shock.
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Introduction
Sepsis, a major health problem in the United States, is a top 15 leading
cause of death (Heron, 2019). Approximately 50% of all hospital deaths are
attributed to sepsis and over 2.5 million cases were reported between January
2010 and September 2016 (Liu et al., 2014; Paoli, Reynolds, Sinha, Gitlin, &
Crouser, 2018). The definitions for sepsis and septic shock are constantly
evolving as clinicians learn more about this complex disease process. Sepsis is
defined as the body’s response to an infection that results in life-threatening
organ dysfunction (Singer et al., 2016). Septic shock is defined as sepsis that
requires intravenous vasopressors to maintain a mean arterial pressure (MAP) of
> 65 mm Hg and the presence of a serum lactate level > 2 mmol/L (>18 mg/dL)
after volume resuscitation (Singer et al., 2016). The mortality rate varies based
on the severity of disease, but the use of vasopressors increases the mortality to
greater than 50% (Mayr, Yende, & Angus, 2014; Brown et al., 2013). Causes of
death are multifactorial, but because vasopressors have a narrow therapeutic
window, they can pose harmful effects. Adverse effects associated with
vasopressor use include ischemia and arrhythmias (Morelli et al., 2013).
Weaning patients off vasopressors as soon as possible should help improve
outcomes in view of lower complications.
The Surviving Sepsis Guidelines recommend maintaining MAP > 65
mmHg in patients with septic shock, a recommendation largely based on clinical
experience and the concept of renal autoregulation of blood flow (Rhodes et al.,
2017). Few studies have examined vasopressor titration by ICU nurses to
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maintain target MAP. Researchers in three studies (Asfar et al., 2014;
Lamontagne et al., 2016; Poukkanen et al., 2013) found poor compliance with
titration and noted MAP was often 5 mmHg higher than the target range desired.
A small pilot study examined the use of simulator technology to improve nursing
vasopressor titration skills (Fadale, Tucker, Dungan, & Sabol, 2014). Prior to
simulated training, nurses averaged over 5 minutes to correctly initiate the first
titration of vasopressors and some nurses, citing nurse preference, chose to
deviate from titration protocols by reducing dose increments (Fadale, Tucker,
Dungan, & Sabol, 2014). Regulatory agencies such as the Joint Commission
have noted this trend and released medication management standards to
maintain consistent administration practices and decrease variation among
nurses (The Joint Commission, 2019). However, Chen et al. (2019) found that
detailed titration instructions increased the amount of time for hemodynamic
stability. Some studies have found success with the use of closed loop
controllers to improve titration and reduce norepinephrine dosing (Rinehart, Ma,
Calderon, & Cannesson, 2018; Joosten et al., 2019; Merouani et al., 2008), but
these have yet to be instituted on a large scale in the clinical setting.
The following is a descriptive study to further understand nurse titration of
vasopressors and calculate rates for events of failure to titrate, incorrect titration,
and correct titration. Hospital and ICU lengths of stay, mortality rate, total
vasopressor administration dose and duration, and the impact of hydrocortisone
on vasopressor use were examined. For the latter, the cases with septic shock
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on vasopressors were stratified into two cohorts (with and without corticosteroid
treatment), between which the study outcomes were compared.
Materials and Methods
Study Design and Participants
This single-unit, retrospective, descriptive study was conducted with
electronic health records (EHRs) from the 24-bed Medical Intensive Care Unit
(MICU) of a 933-bed tertiary care hospital in the Texas Medical Center.
The research protocol was approved by the institutional review board at
both the University of Texas Health Science Center at Houston and the hospital.
A convenience sample of adults ≥ 18 years old were enrolled if they had sepsis
with vasodilatory, volume-refractory shock necessitating administration of
vasopressor therapy for ≥ 4 hours to maintain MAP ≥ 65 mmHg. Patients were
excluded from the study for any of the following: other possible types of shock
(i.e., hypovolemic, cardiogenic, obstructive, or neurogenic); inadequate volume
resuscitation (CVP < 6 mmHg or urinary output < 30 cc/hr in the presence of
normal renal function); unlikely infectious process; pregnancy (risk of aortocaval
compression syndrome); severe head injury; transition to comfort care; and
status post cardiac arrest.
Data Collection
Using the electronic health record (EHR), all patients admitted to the
MICU between December 1, 2017 and December 31, 2018 were screened for
eligibility. Demographic, Acute Physiology and Chronic Health Evaluation II
(APACHE II), and Sequential Organ Failure Assessment (SOFA) data were
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collected; for APACHE II and SOFA, the most abnormal values recorded during
the first 24 hours following ICU admission were used. Three patients had missing
data for pH and the weight of these values was corrected using a clinical
calculator (QxMD.com, 2019). Corticosteroid use was defined as any use of
hydrocortisone in doses of ≥ 200 mg/day for ≥ 24 hours, per Surviving Sepsis
Guidelines (Rhodes et al., 2017). Total vasopressor dose was computed based
on norepinephrine equivalents (Table 1). Interrater reliability of these data was
assessed quarterly throughout data collection; values of ≥.80 were considered
acceptable (Landis & Koch, 1977).
Titration variables (failure to titrate, incorrect titration, and correct titration)
were based on the hospital’s required documentation of blood pressure every 15
min while patients are on vasoactive drug therapy. Data were classified as
failure-to-titrate events when nurses did not titrate vasopressors despite
supportive and corresponding MAP documentation indicating titration was
warranted. Data were classified as incorrect titration when upward or downward
titration of vasopressors was inconsistent with corresponding MAP
documentation. Titration data were classified as correct titration when nurses
accurately titrated vasopressors per hospital protocol to maintain MAP 65-70
mmHg based on the documented blood pressure. Data were classified as
titration not indicated when the nurse did not titrate vasopressors because the
MAP was in the prescribed range. Although monitoring of MAP directly with an
arterial catheter is the optimal measurement (Rhodes et al., 2017), a minority of
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eligible patients had an arterial catheter; therefore, noninvasive blood pressure
(NIBP) was used for the majority.
Data Management and Analysis
SPSS (version 26.0, IBM Corp) and Excel (version 15.28, Microsoft)
software programs were used for data management and analysis. Descriptive
statistics were used for patient demographics and clinical characteristics.
Normality of scale variables was assessed by reviewing the histograms and
skewness and kurtosis statistics. Interrater reliability of data collection was
assessed with percentage agreement. Differences between patients who did and
did not receive corticosteroids were compared with the independent samples ttest, Mann-Whitney U test, Pearson Chi-square, and Fisher’s Exact Test. Cox
regression was used to evaluate the impact of corticosteroids on total time
receiving vasopressors while controlling for acuity of illness with APACHE II and
SOFA scores. Alpha was .05 for all analyses.
Aggregate and median values of vasopressor time, vasopressor dose,
failure to titrate, incorrect titration, and correct titration were calculated.
Aggregate failure to titrate, incorrect titration, and correct titration were divided by
aggregate vasopressor time to establish titration events per hour. Based on the
assumption that nurses had four opportunities to titrate within 1 hour (MAP
documented every 15 min), values were calculated and displayed graphically.
Results
The investigator assessed 1078 consecutive patients admitted to the
MICU for study eligibility. Most of these patients (n = 972) were not eligible for
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participation because they did not meet the inclusion criteria for septic shock;
others were excluded for the reasons shown in Figure 1. Data collection and
analysis were completed on 60 patients. Interrater reliability was .80.
Sample Characteristics. Table 2 shows the characteristics of the entire
sample and the subsamples of patients who did and did not receive
corticosteroids. Almost half of patients (48%) had septic shock present on
admission with 80% demonstrating either integumentary, pulmonary,
gastrointestinal, or genitourinary causes of sepsis. Microbial cultures were
positive in 77% of the sample. Most of the patients (73%) did not have an arterial
line.
Study Variables. Vasopressor dose and time, hospital and ICU lengths of
stay, failure to titrate, incorrect titration, and correct titration variables were
abnormally distributed, and are presented in Table 2 as median (interquartile
range, IQR).
During the total vasopressor infusion time of 2598 hours, 5395 failure-totitrate events were noted. There were 316 incorrect titrations, 704 correct
titrations, and 3977 15-minute time intervals when titration was not indicated.
Converting the aggregate titration opportunities to an hourly rate, and based on
documentation of MAP at 15-minute intervals, the failure-to-titrate hourly rate was
50%; the correct-titration hourly rate was 48% (correct titration and titration not
indicated); and the incorrect- titration rate was 2% (Figure 2). Three patients died
after excluding those who transitioned to comfort care.
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Impact of Corticosteroids. Patient demographics and clinical
characteristics were generally similar between patients who received
corticosteroids and those who did not (Table 2); however, total vasopressor dose
was statistically and clinically significantly greater in the corticosteroid
subsample. Patients with higher acuity score were more likely to receive
corticosteroids than those with lower acuity score. Mean APACHE II and SOFA
scores were 2 points higher in those who received steroids. When controlling for
acuity of illness with APACHE II or SOFA scores, Cox regression showed no
meaningful difference (expB 0.97, 95% CI [0.93, 1.02], p=.18 for APACHE II and
expB 1.05, 95% CI [0.95, 1.16], p = .31 for SOFA) in time on vasopressors
between subsamples (Figure 3).
Presence of Arterial Catheter. Demographic data and clinical
characteristics were variable between those who had an arterial catheter and
those who did not (Table 3). Patients with an arterial catheter had higher acuity of
illness scores; longer ICU stay; and proportionately higher total vasopressor
dose, time, and variety of vasopressor use than patients without an arterial
catheter. Those with an arterial catheter had a double or more increase in failureto-titrate and incorrect-titration rates compared with patients who had NIBP
monitoring.
Discussion
The findings of this study showed that, in one MICU, nurses made
appropriate titration decisions nearly half the time patients with septic shock were
on vasopressor therapy. Incorrect titration was relatively rare. However, nurses
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failed to execute titration a considerable percentage of time, which would be
expected to prolong vasopressor therapy, thereby placing patients at risk for
adverse effects. Prolonged vasopressor therapy could also increase ICU length
of stay, which would place the patient at a higher risk of hospital complications
and a higher cost of care.
Appropriate titration events far exceeded incorrect titrations. The
investigator did not formally examine whether or not the nurse followed the exact
dose ordered when titrating vasopressors, only whether or not the titration
response was appropriate for the documented MAP. The 5mmHg range of the
target MAP may be too narrow. Several other studies have noted poor
compliance with titration when the range of the target MAP is 5mmHg, as it
relates to higher versus lower blood pressure targets and the impact on sepsis
outcomes (Asfar et al., 2014; Lamontagne et al., 2016; Poukkanen et al., 2013).
Variability of MAP in ICU patients exceeds 5mmHg during steady states (Hamlin,
Hanneman, Padhye, & Lodato, 2015), a finding that argues for a target MAP
range > 5 mmHg for vasopressor titration.
Deviations from the titration protocol without corresponding MAP
documentation, labeled as incorrect titration in this study, had the lowest rate
(2%) of the titration events. It was noted that these deviations often had abnormal
dosing amounts that did not follow the titration protocol. Fadale et al. (2014)
noted a similar trend and nurse justification included that the titration dosing
order seemed too aggressive. Rapid changes in patient condition in the ICU may
warrant more or less aggressive titration. As noted by Chen and colleagues
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(2019), detailed titration instructions increased the amount of time for
hemodynamic stability. Therefore, nurses should retain autonomy in the titration
of vasopressors, which is within their scope of practice. One patient was
excluded from this study due to poor documentation of vital signs and, thus,
inability to calculate titration changes. EHR review is imperfect and does not
always reflect events in the ICU. During critical situations, it may be difficult for
the nurse to generate documentation while providing life-sustaining care.
The inclusion of vasopressin offered a unique set of challenges.
Vasopressin dosing for septic shock is measured in units per minute compared
with micrograms per minute for norepinephrine, phenylephrine, and epinephrine.
Vasopressin dosing is also not weight based and only recommended in doses of
0.03 units/minute or 0.04 units/minute for patients with septic shock (Rhodes et
al., 2017). This required conversion of vasopressin, epinephrine and
phenylephrine to norepinephrine equivalents (Table 1) (Chawla et al., 2017;
Brown et al., 2013). Vasopressin also has a longer half-life requiring a deviation
in titration methodologies (Arellano & Hanneman, 2014). Hemodynamic changes
after the initiation of vasopressin were common. There was often a delay in the
downward titration of other vasopressors after initiation of vasopressin, which
may have impacted the failure-to-titrate rate.
Corticosteroid use was identified as a potential confounding variable for
vasopressor titration, albeit this study was not adequately powered to examine
the effect of corticosteroids on vasopressor dose and time. To compare the
corticosteroid subgroups for time on vasopressor therapy, Cox regression was
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used to control for acuity of illness. Because the acuity scores were highly
correlated (r = 0.76), separate models were tested for the APACHE II and SOFA
scores. No significant difference was found between the groups in vasopressor
time. This finding is likely secondary to a small sample size and is not
comparable to the findings of larger trials (Venkatesh et al., 2018; Sprung et al.,
2008). Several extreme outliers in the data precluded analysis of the impact of
corticosteroids on vasopressor dose when controlling for APACHE II and SOFA
scores using linear regression; multiple iterations failed to produce adequate
statistical models, and removal of outliers led to model deterioration.
Only 27% of the small sample had an indwelling arterial catheter,
considered the optimal way to measure MAP. National initiatives such as the
Choosing Wisely Campaign (American Board of Internal Medicine Foundation,
2019) now emphasize a noninvasive approach to care and treatment of ICU
patients. In this study, patients with arterial catheters had routine monitoring of
blood pressure and correlation with NIBP was performed clinically.
The proportionately higher aggregate dose and aggregate vasopressor
time is consistent with the higher acuity scores, demonstrating that higher acuity
patients are more likely to require an arterial catheter. The higher failure-totitrate and incorrect- titration rates seen in those with an arterial catheter is likely
related to higher dosages and number of vasopressors for those with an arterial
catheter, compared with the patients who had only NIBP monitoring. The use of
an arterial line in the setting of more than one vasopressor is consistent with
most guidelines for the management of septic shock (Rhodes et al., 2017).
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There were limitations to the present study. Patients in this study received
low-to-moderate doses of vasopressors, an observation that may be explained
by exclusion of patients who transitioned to comfort care. Vasopressor titration is
often less aggressive once discussions about comfort care are initiated or when
patients are deemed “no escalation of care” (Morgan, Varas, Pedroza, &
Almoosa, 2014). Ineligibility of these patients introduces selection bias; however,
vasopressor titration patterns would not be valid without the ability to escalate
vasopressor dosage. This exclusion criterion also falsely improved the mortality
rate in this sample of patients with septic shock. All patients excluded and
transitioned to comfort care died (n=27). When these results are included in the
mortality rate calculation, they yield a mortality of 34% that is consistent with the
national average. Lastly, our cohort was largely Caucasian, with little ethnic
diversity, and had a mean age of 61 years. Therefore, the sample characteristics
and size limit generalizability of the findings.
Anecdotal Observations
Analysis of nurse vasopressor titration patterns was not located in the
literature, and the following anecdotal observations may stimulate systematic
study of titration patterns to identify time points and events for possible
intervention. First, nurses were more likely to titrate vasopressors (upward or
downward) during medication bag replacement. Second, nurses were less likely
to titrate vasoactive therapy while outside of the ICU environment for a procedure
or diagnostic test. Third, titrations notably decreased 2 hours before shift change
but then increased after shift change. If a titration was attempted several times
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without success, nurses were less likely to attempt titration again within that hour.
Lastly, patients on continuous venous-to-venous hemodialysis were less likely to
receive aggressive vasopressor titration. Systematic study of titration patterns
could validate these anecdotal findings.
Conclusions and Implications
The results of this study suggest that failure-to-titrate vasopressor rates
are high in MICU patients with septic shock. The impact of corticosteroids on
sepsis outcomes remains a point of debate; in this study, use of corticosteroids
was directly associated with severity of illness. There was no demonstrable
clinically or statistically significant difference in the effect of corticosteroids on
vasopressor dose or duration of therapy. A larger sample size is indicated to
further explore this topic. Anecdotal observations suggest the value of future
research exploring vasopressor titration patterns in ICU patients with septic
shock and possible care delivery points for intervention.

46
Summary of Key Points


The Surviving Sepsis Guidelines recommends a MAP of > 65 mmHg in
patients with septic shock. Few studies have examined vasopressor titration
patterns to maintain this target MAP. Weaning vasopressors off sooner
should help to improve patient outcomes because vasopressors have a
narrow therapeutic window and can produce harmful effects.



Practical bedside implications include: 1) Failure-to-titrate rates are high in
ICU patients with septic shock. 2) Weaning vasopressors off sooner should
help to improve patient outcomes by reducing such complications of
vasopressor use as ischemia and arrhythmias. 3) Patients with higher acuity
of illness scores are more likely to receive corticosteroid therapy than those
with lower acuity.
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Table 1
Dose Equivalents of Vasopressors
VASOPRESOR

NOREPINEPHRINE NOREPINEPHRINE
EQUIVALENT
(mg)
Norepinephrine (mg)
1
1

a

Epinephrine (mg)

1

1

Phenylephrine (mg)

10

1

Vasopressina (units)

4

1

Approximate conversion dose of vasopressin normalized to 100 Kg of body
weight.
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Table 2
Patient Demographics and Clinical Characteristics: Steroid vs Non-Steroid
Groups
Characteristic

Total Sample Steroid
Group
(n=32)
Age, range (mean [SD]), y
22-90 (61
29-90 (60
[16.7])
[16.8])
Female, No. (%)
30 (50)
15 (50)
Ethnicity, No. (%)
Not Hispanic/Latino
Hispanic/Latino
Race, No. (%)
Amer Ind/Alaska
Native
Black or African Amer
Caucasian
Advanced Directive, No.
(%)
None
DNR
ICU/Hospital Mortality,
No. (%)
Positive Culture at
Discharge, No. (%)
Yes
No
Arterial Catheter, No. (%)
Yes
No
APACHE II Score,b range
(mean [SD])
SOFA Score,c range
(mean [SD])
Hospital LOS in days,
range (median [IQR])
ICU LOS in days, range
(median [IQR])
Vasopressors, No (%)
Norepinephrine
Epinephrine

Non-Steroid
Group
(n=28)
22-86 (63
[16.8])
15 (50)

pa
.55
.61
.80

48 (80)
12 (20)

26 (81)
6 (19)

22 (79)
6 (21)

1 (2)
12 (20)
47 (78)

0 (0)
7 (22)
25 (78)

1 (3)
5 (18)
22 (79)

.44

.89
56 (93)
4 (7)

30 (94)
2 (6)

26 (93)
2 (7)

3 (5)

3 (9)

0 (0)

.24
.74

46 (77)
14 (23)

24 (75)
8 (25)

22 (79)
6 (21)

16 (27)
44 (73)
12-53
(24 [8.5])
3-20
(9 [3.1])
1-71
(14 [15.1])
1-22
(4 [4.2])

11 (34)
21 (66)
12-53
(25 [9.8])
3-20
(10 [3.5])
1-71
(14 [22.1])
1-18
(4 [6.0])

5 (18)
23 (82)
13-41
(23 [6.7])
5-14
(8 [2.4])
3-40
(14 [12.8])
1-22
(4 [2.9])

58 (97)
4 (7)

31 (97)
3 (9)

27 (96)
1 (4)

.24
.53
.08
.59
.81
.24
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Vasopressin
Phenylephrine
Total Vasopressor Time
in hours, range (median
[IQR])
Total Vasopressor Dose
in mg,d range (median
[IQR])
Primary Diagnosis, No.
(%)
Nervous System
Integumentary
Cardiovascular
Pulmonary
Gastrointestinal
Genitourinary
Othere
Primary Infectious
Diagnosis, No. (%)
Nervous System
Integumentary
Cardiovascular
Pulmonary
Gastrointestinal
Genitourinary
Otherf
Aggregate Vasopressor
time, hours
Aggregate Vasopressor
dose, mg
Aggregate Failure to
titrate, No.
Aggregate Incorrect
titration, No.
Aggregate Correct
titration, No.

11 (18)
7 (12)

9 (28)
3 (9)

2 (7)
4 (14)
.41

8-229
(35 [32.0])

9-229
(36 [35.3])

8-74
(33 [32.3])
.03*

0.3-312
(12 [24.9])

2-312
(16 [31.8])

0.3-62
(9 [14.3])

3 (5)
7 (12)
2 (3)
9 (15)
4 (7)
6 (10)
29 (48)

2 (6)
2 (6)
0 (0)
6 (20)
2 (6)
2 (6)
18 (56)

1 (4)
5 (18)
2 (7)
3 (11)
2 (7)
4 (14)
11 (39)

.27

.58
1 (2)
12 (20)
1 (2)
12 (20)
13 (22)
14 (23)
7 (11)

0 (0)
6 (19)
0 (0)
8 (25)
8 (25)
7 (22)
3 (9)

1 (4)
6 (21)
1 (4)
4 (14)
5 (18)
7 (25)
4 (14)
.41

2598

1647

951
.03*

1713

1342

371

5395

3479

1916

316

211

105

704

395

309

.45
.18
.68

Abbreviations: Amer, American; APACHE, Acute Physiology and Chronic Health
Evaluation; ICU, intensive care unit; Ind, Indian; IQR, interquartile range; LOS,
length of stay; SD, standard deviation; SOFA, Sequential Organ Failure
Assessment.
a
Independent samples t-test used for age, APACHE II and SOFA score; MannWhitney U test used for Total Vasopressor Dose, Total Vasopressor Time,
Hospital LOS, ICU LOS, Aggregate Vasopressor Time, Aggregate Vasopressor
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Dose, Aggregate Failure to titrate, Aggregate Incorrect titration, Aggregate
Correct titration; Pearson χ2 and Fisher’s Exact Test were used for Female,
Ethnicity, Race, Advanced Directive, ICU/Hospital Mortality, Positive Culture at
Discharge, Primary Diagnosis, Primary Infectious Diagnosis, and Arterial
Catheter.
b
APACHE II score varies from 0 to 71, with higher score associated with greater
severity of illness and risk of death; modified Glasgow Coma Scale was used to
compute APACHE II score.
c
SOFA score varies from 0 to 24, with higher score associated with more severe
organ failure; modified Glasgow Coma Scale was used to compute SOFA score.
d
Total vasopressor dose calculated in norepinephrine equivalents with
vasopressin normalized for a patient weighing 100 Kg.
e
Primarily septic shock.
f
Primarily bacteremia from unclear source.
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Table 3
Patient Demographics and Clinical Characteristics: Arterial Catheter vs No
Arterial Catheter
Characteristic
Age, range (mean [SD]),
y
Female, No. (%)
Ethnicity, No. (%)
Not Hispanic/Latino
Hispanic/Latino
Race, No. (%)
Amer Ind/Alaska
Native
Black or African Amer
Caucasian
Advanced Directive, No.
(%)
None
DNR
ICU/Hospital Mortality,
No. (%)
Positive Culture at
Discharge, No. (%)
Yes
No
Corticosteroid Use, No.
(%)
Yes
No
APACHE II Score,b
range (mean [SD])
SOFA Score,c range
(mean [SD])
Hospital LOS in days,
range (median [IQR])
ICU LOS in days, range
(median [IQR])
Vasopressors, No (%)
Norepinephrine
Epinephrine
Vasopressin
Phenylephrine

Total
Sample
22-90 (61
[16.7])
30 (50)

Arterial
Catheter
(n=16)
22-86 (58
[19.8])
5 (31)

No Arterial
Catheter
(n=44)
28-90 (63
[15.5])
25 (57)

pa
.37
.08
.19

48 (80)
12 (20)

11 (69)
5 (31)

37 (84)
7 (16)
.63

1 (2)
12 (20)
47 (78)

0 (0)
4 (25)
12 (75)

1 (2)
8 (18)
35 (80)

56 (93)
4 (7)

16 (100)
0 (0)

40 (91)
4 (9)

3 (5)

2 (13)

1 (2)

.21

.17
.23

46 (77)
14 (23)

14 (88)
2 (12)

32 (73)
12 (27)

32 (53)
28 (47)

11 (31)
5 (69)

21 (52)
23 (48)

12-53
(24 [8.5])
3-20
(9 [3.1])
1-71
(14 [15.1])
1-22
(4 [4.2])

16-53
(30 [10.0])
5-20
(11 [3.6])
1-70
(17 [17.8])
1-22
(6 [10.0])

12-36
(22 [6.8])
3-14
(8 [2.6])
3-71
(13 [14.5])
1-18
(4 [3.1])

58 (97)
4 (7)
11 (18)
7 (12)

15 (94)
4 (3)
7 (44)
3 (2)

43 (98)
0 (0)
4 (1)
4 (1)

.15

.001*
.004*
.34
.05*
.003*
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Total Vasopressor Time
in hours, range (median
[IQR])
Total Vasopressor Dose
in mg,d range (median
[IQR])
Primary Diagnosis, No.
(%)
Nervous System
Integumentary
Cardiovascular
Pulmonary
Gastrointestinal
Genitourinary
Othere
Primary Infectious
Diagnosis, No. (%)
Nervous System
Integumentary
Cardiovascular
Pulmonary
Gastrointestinal
Genitourinary
Otherf
Aggregate Vasopressor
time, hours
Aggregate Vasopressor
dose, mg
Aggregate Failure to
titrate, No.
Aggregate Incorrect
titration, No.
Aggregate Correct
titration, No.

.04*
8-229
(35 [32.0])

11-229
(47 [39.6])

8-194
(30 [28.7])

0.3-312
(12 [24.9])

3-312
(28 [43.7])

0.3-260
(11 [16.3]

.03*
.08
3 (5)
7 (12)
2 (3)
9 (15)
4 (7)
6 (10)
29 (48)

2 (13)
0 (0)
0 (0)
1 (6)
2 (13)
1 (6)
10 (62)

1 (2)
7 (16)
2 (5)
8 (18)
2 (5)
5 (11)
19 (43)
.77

1 (2)
12 (20)
1 (2)
12 (20)
13 (22)
14 (23)
7 (11)

0 (0)
2 (12)
0 (0)
4 (25)
4 (25)
3 (19)
3 (19)

1 (2)
10 (23)
1 (2)
8 (18)
9 (21)
11 (25)
4 (9)

2598

946

1652

1713

836

877

.04*
.03*
.03*
5395

3274

2121
.05*

316

135

181
.23

704

242

462

Abbreviations: Amer, American; APACHE, Acute Physiology and Chronic Health
Evaluation; ICU, intensive care unit; Ind, Indian; IQR, interquartile range; LOS,
length of stay; SD, standard deviation; SOFA, Sequential Organ Failure
Assessment.
a
Independent samples t-test used for age, APACHE II and SOFA score; MannWhitney U test used for Total Vasopressor Dose, Total Vasopressor Time,
Hospital LOS, ICU LOS, Aggregate Vasopressor Time, Aggregate Vasopressor
Dose, Aggregate Failure to titrate, Aggregate Incorrect titration, Aggregate
Correct titration; Pearson χ2 and Fisher’s Exact Test were used for Female,
Ethnicity, Race, Advanced Directive, ICU/Hospital Mortality, Positive Culture at
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Discharge, Primary Diagnosis, Primary Infectious Diagnosis, and Arterial
Catheter.
b
APACHE II score varies from 0 to 71, with higher score associated with greater
severity of illness and risk of death; modified Glasgow Coma Scale was used to
compute APACHE II score.
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One Hour on Vasopressors
8%

2%

50%
40%

Failure to Titrate

Titration Not Applicable

Correct Titration

Incorrect Titration

Figure 2. Titration Model for 1 Hour of Vasopressor Therapy. Values based on
aggregate titration data divided by aggregate vasopressor hours. The failure-totitrate rate was 50% for one hour throughout the duration of vasopressor therapy.
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Figure 3. Cox Regression Survival Analysis comparing those who received
corticosteroids and those who did not when controlled for APACHE II score.
ExpB value of 0.97, 95% CI [0.93, 1.02], p=.18 for APACHE II demonstrates an
unlikely relationship between corticosteroid use and time on vasopressors.
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Instruments:
1.

Arterial catheter (18-gauge, radiopaque, Arrow International)

Arrow Arterial Catheterization Kit
Catheter Cable

General Electric Medical Systems Arterial
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Bedside physiologic monitor (Carescape, General Electric Medical Systems
Information Technologies).

General Electric monitor

71
Pressure transducer (PXMK2011, Edwards Lifesciences)
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Viewing alarm parameters on Carescape, General Electric Monitor
PREFERRED METHOD
1)
2)
3)
4)
5)
6)
7)
8)
9)

Ensure that the arterial catheter transducer is secured to the monitor
cables.
Touch the upper right portion of the monitor screen with the patient
identifying information.
Locate the profile tab.
Change to ART (blood pressure information should appear IN RED on the
right side of the screen.
Select the arterial catheter information in RED.
Select the alarms tab.
Ensure high MAP at 110mmHg.
Ensure low MAP at 55mmHg.
Press Exit.

ALTERNATIVE METHOD
1)
2)
3)
4)
5)
6)

Ensure that the arterial catheter transducer is secured to monitor cables.
Press “Alarm Set up” in the left bottom portion of the monitor screen.
Locate the arterial catheter alarm parameters at the bottom of the screen.
Ensure high MAP at 110mmHg.
Ensure low MAP at 55mmHg.
Press Exit.
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Changing alarm parameters on Carescape, General Electric Monitor
(Intervention Group)
PREFERRED METHOD
1) Ensure that the arterial catheter transducer is secured to the monitor cables.
2) Touch the upper right portion of the monitor screen with the patient identifying
information.
3) Locate the profile tab.
4) Change to ART (blood pressure information should appear IN RED on the right
side of the screen.
5) Select the arterial catheter information in RED.
6) Select the alarms tab.
7) Change high MAP at 70mmHg.
8) Leave low MAP at 55mmHg.
9) Press Exit.
ALTERNATIVE METHOD
1)
2)
3)
4)
5)
6)

Ensure that the arterial catheter transducer is secured to monitor cables.
Press “Alarm Set up” in the left bottom portion of the monitor screen.
Locate the arterial catheter alarm parameters at the bottom of the screen.
Change high MAP at 70mmHg.
Leave low MAP at 55mmHg.
Press Exit.
For a demonstration, please visit the following link on YouTube:
https://youtu.be/Jl0cahbMy-Q

74
Calibration of Arterial Catheter (Hamlin, 2010)
The catheter must be appropriately placed and without visible kinks. Arterial
pressure monitoring connections must be secure. The pressure bag flush system
must be adequately inflated (>300 mmHg) by inspecting the pressure indicator.
All air bubbles and blood must be removed from the tubing system. The
transducer must be appropriately aligned at the level of the phlebostatic axis by
using a ruler. The system must be zeroed to compensate for the offset caused by
pressure differences in the transducer, amplifier, oscilloscope, recorder, and
digital display. Calibration and square wave testing must also be performed to
ensure accuracy of measurement. The monitor display must be set to measure
the arterial pressure and display the waveform of arterial measurement. The
MAP is calculated by the physiologic monitor and is displayed after the systolic
and diastolic pressure readings within parentheses.
1) Check all arterial pressure monitoring connections are secure
2) Check pressure bag adequately inflated by inspecting white pressure indicator
 Knob is protruding outward with pressure line visible indicating at least
300 mm Hg pressure (Darovic & Zbilut, 2002)
3) Inspect pressure monitoring system tubing and connections for air bubbles
 If air bubbles present, remove with 3 cc syringe and discard
 Flush arterial pressure monitoring system with rapid flush pigtail, until all
visible blood is removed from pressure monitoring system
4) Ensure arterial catheter tubing and connections remain off patient
 Even minimal movement of the pressure monitoring tubing produces an
externally induced whip artifact from movement of the fluid within the
system (Darovic & Zbilut, 2002)
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(Gardner & Hujcs, 1993)
5) Level the transducer using 30 cm ruler aligned at level of the transducer and
the mid-heart or mid-axillary line (Gardner & Hollingsworth, 1986)
 Most important step in pressure monitoring system (Gardner & Hujcs,
1993)
 Zeroing process compensates for offset caused by hydrostatic pressure
differences in the transducer, amplifier, oscilloscope, recorder, and digital
displays (Gardner, 1992)

(Gardner & Hollingsworth, 1986)
6) Turn the stopcock closest to the transducer to the horizontal position (off to the
pressure system) and open to atmospheric pressure
7) Press the zero button on the bedside physiologic monitor
8) Observe the numeric reading of arterial pressure reads zero
9) Return the stopcock arm to the vertical position (opening the pressure system)
10) Re-zero transducer with any change in HOB or lateral position change
11) Perform calibration to verify accurate reproduction of the pressure signal
using the hydrostatic pressure method (Darovic & Zbilut, 2002)
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Attach flushed 24-inch noncompliant tubing to transducer stopcock at the
“zeroing port” and cap distal end (Hazinski, 2002)
 Uncap the distal end of the tubing and the transducer stopcock is turned
“open” between the transducer and tubing (“off” to patient)
 When the uncapped distal end of the tubing is held at the zero reference
point (mid-heart or mid-axillary line) the monitor should display a pressure
of 0
12) Check the dynamic response of the system using square wave test
 Dynamic response is the ability of the fluid-filled pressure monitoring
system to accurately reproduce pressure variations of the arterial pressure
signal on the amplifier/monitor (Darovic & Zbilut, 2002; Imperial-Perez &
McRae, 1997)
 Two factors affect systems accuracy (Imperial-Perez & McRae, 1997)
 Natural frequency (fn), which refers to the number of oscillations per
second, produced by the system after it is exposed to a pressure signal
and
 Damping coefficient
 Evaluate the response generated on the bedside physiologic monitor
when the rapidly closing valve on the continuous flush device (fast flush) is
activated and released quickly
Optimally Damped System
 Waveform shows sharp upstroke which terminates in a flat line at the
maximal indicator and
 Followed by an immediate and rapid downstroke which extends below the
baseline with only 1 or 2 oscillations within 0.12 second (minimal ringing)
with a quick return to baseline

(Imperial-Perez & McRae, 1997)
i. Intervention:
1. No adjustment necessary
Overdamped System
 Waveform shows slurred upstroke of square wave, when waveform does
not extend below baseline after rapid flush, and there is no ringing after
flush
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(Imperial-Perez & McRae, 1997)


Intervention:
1. Check for blood clots, blood in catheter, or air bubbles in the system
and remove with 3 cc syringe
2. Check for kinks in line
3. Check all connections secure
4. Repeat and print square wave test and evaluate
5. If after 3 repeated square wave tests, system indicates overdampened
system, notify site coordinator within 10 minutes
6. Study coordinator will document in the audit check list

Underdamped System
 Waveform characterized by numerous oscillations above and below
baseline following fast-flush
 Monitored pressure wave displays false-high systolic pressure (overshoot)
and possibly false-low diastolic pressure with ringing artifacts on waveform

(Imperial-Perez & McRae, 1997)


Intervention:
1. Remove all air bubbles from system (especially pinpoint air bubbles)
with 3 cc syringe
2. Repeat and print square wave test and evaluate
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3. If after 3 repeated square wave tests, system indicates overdampened
system, notify site coordinator within 10 minutes
4. Study coordinator will document in the audit check list
13) Repeat steps as needed: (Imperial-Perez & McRae, 1997)
 If the accuracy of the pressure readings is questioned and/or
 After disconnection of the transducer from the pressure cable
 Once every 12 hours
14) The arterial catheter MAP will be correlated with the non-invasive MAP at
least every 12 hours to ensure a comparison with the arterial catheter.
 Additional correlations may be required if the accuracy of the pressure
readings is questioned.
 If the arterial line accuracy is called into question, the blood pressure cuff
should be changed to another site for comparison.
 If continued readings are inaccurate, the patient may be withdrawn from
the protocol.
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Data Collection Procedure from the Electronic Medical Record (Epic):
Screening Procedure:
1) Click the EPIC icon
2) Enter user ID and password; click login
3) Select appropriate department
4) Click ok
5) Select patient list tab
6) Locate available list tab
7) Locate system list
8) Select system list
9) Select HMH
10) Select units
11) Locate Fondren MICU
12) Select Fondren MICU
13) Locate desired patient
14) Double click patient name
15) Produce study ID number
a. C (Control) XXX
b. E (Experimental) XXX
16) From default summary tab. Click, “Facesheet”
17) Collect bed number
18) Scroll to bottom and Collect MRN


Procedure after Recruitment

19) Click Patient List Icon
20) Click Patient Lookup
21) Enter MRN in MRN box
22) Verify Patient and Click Enter
23) Locate desired admission date with bed icon
24) Select “Encounter” from Chart Review bar
25) Collect bed number
26) From default summary tab. Click, Facesheet
27) Collect age from top banner or Facesheet
28) Collect Gender from top banner or Facesheet
29) Collect Ethnicity
30) Collect Race
31) From top banner, collect code status/Advanced Directive Status
32) Click Blue Underlined Text for full details if needed
33) Click Chart Review Tab
34) Click encounters
35) Click Patient encounter date
36) Scroll to “Care Timeline”
37) Collect Hospital admission date and time
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38) Collect ICU admission date and time
39) Collect ICU discharge date and time
40) Collect Hospital discharge date and time
41) Collect Hospital discharge status
 Medication Information:
42) Click Orders tab
43) Click orders history
44) Click since admit
45) Click “Order” tab to alphabetize orders
46) Scroll to locate hydrocortisone
47) Click hydrocortisone
48) On second screen below, scroll, locate and click, “Full administration report”
49) Calculate hydrocortisone dosing and collect as appropriate
50) Scroll to locate norepinephrine
51) Click norepinephrine
52) On second screen below, scroll, locate and click, “Full administration report”
53) Ensure vasopressor therapy length meets protocol standards
54) Repeat as appropriate for vasopressin
55) Repeat as appropriate for epinephrine
56) Repeat as appropriate for phenylephrine
57) Collect Vasopressor Length data
a. Note Vasopressor Start time under “full administration report”
b. Note Vasopressor Start time under “full administration report”
 Vasopressor dose Collection:
58) Click Intake/Output tab on the left side of screen
59) Click the Calendar icon next to date
60) Select Appropriate Dates of vasopressor use/admission
61) Click magnifying glass Next to “Shift”
62) Select “24 hour”
63) Click 2 downward arrows next to “IV”
64) Click rightward > Arrow next to Calendar icon and date
65) Collect vasopressor volume for first vasopressor use during first ICU
admission
66) Repeat for each applicable vasopressor
67) If multiple concentrations are noted. Note start and stop time for each bag
68) Manually calculate each date as appropriate
 Vital Signs:
69) Click summary tab
70) Click flowsheet
71) Click calendar icon
72) Enter date range of MICU admission
73) Locate worst Vital signs within 24 hours of MICU admission
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a.
b.
c.
d.
e.
f.

Temp
RR
HR
MAP
Fio2
Spo2

74) Collect vent/oxygen data
75) Collect GCS within 24 hours of MICU admission (brown data)
76) Collect intubation status within 24 hours of MICU admission
77) Collect “Degree of hypotension” data based on weight listed on heading bar.
 Laboratory Data:
78) Click “Labs” from the Summary tab
79) Click calendar icon
80) Enter date range of MICU admission
81) Locate Labs per protocol within 24 hours of MICU admission
a. Pa02
b. HCT
c. WBCs
d. pH
e. Na
f. K
g. Creatinine
h. Hco3
i. Platelets
j. Total bilirubin
82) Click “Micro” from the Summary tab
83) Collect Infectious diagnosis
84) Select Results Review Tab on left
85) Click Laboratory Results
86) Click Infectious Disease and Micro
87) Select “Load All”
88) Select Newest First
89) Collect Positive Culture Data for Infectious Diagnosis and Notes
 Other diagnosis:
90) Select problem list on left access panel
91) Collect primary/principle diagnosis (noted with selected Diamond)
92) Collect infectious diagnosis if applicable
 Arterial Line Yes/No:
93) Click bedside procedures tab
94) Collect arterial line insertion
95) Arterial line presence can also be collected from Flowsheet
96) Sync data with excel spreadsheet
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o Nurse Titration Data:
97) Click View Flowsheet Tab from Menu bar on left
98) Select I/O from tabs on top
99) Select Go to Date on top bar
100) Enter Date of vasopressor start
101) Acknowledge Warning and Continue Loading
102) Note vasopressor start time
103) Collect Correct Nurse Titration Data each hour
104) Collect Failure to Titrate data each hour
105) Collect incorrect downward titration each hour
106) Collect incorrect upward titration each hour
107) Total each and note them on worksheet.
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Audit Procedure
An audit will be performed bi-weekly during the intervention phase of the study. This is
process is paramount to ensure adherence to study protocol and monitor alarm
parameters. Monitors of patients enrolled in the study will be checked at random to
ensure compliance with the protocol. The investigator will track the audit data on the
following data sheet and initial. If a patient enrolled in the intervention group is found to
be off protocol (MAP alarm parameters outside 55-70mmHg), the error will be corrected
and the monitor will be assessed for the duration of time off protocol. In order to continue
to be enrolled, the alarm parameters must be at 80% or higher compliance. Alarm
manipulation times can be found in the bedside patient monitor and at the central
monitoring station.
Patient Study ID Code_________________
Unit Bed Number ______________

Date/Time
Arterial connections Secure
Pressure Bag Inflated
Tubing Free of Air Bubbles
Transducer Leveled to
Mid-Axillary Line
Square Wave Testing
And Interventions
1- Optimally Dampened
2- Over Dampened
3- Under Dampened
Monitor alarm
(Control group)
ABP MAP maximum 110
mmHg
Monitor alarm
(Control group)
ABP MAP minimum 55
mmHg
Monitor alarm
(Intervention group)
ABP MAP maximum 70
mmHg
Monitor alarm
(Intervention group)
ABP MAP minimum 55
mmHg
Arterial Catheter MAP
correlated to Non-Invasive
MAP
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Data Management
The researcher will collect the data and place it on an EXCEL spreadsheet
kept on an encrypted password protected flash drive within a locked cabinet
located at the University of Texas Health Science Center at Houston School of
Nursing. Data will be kept in Excel until transfer into SPSS for statistical analysis.
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An Excel Spreadsheet will contain the following for data collection:







































Study ID number
Bed number
MRN
Age
Gender (1=Male, 2=Female, 3=other)
Hospital admission date and time
ICU admission date and time
Ethnicity (1 =Not-Hispanic/Latino; 2 = Hispanic/Latino)
Race
o 1=American Indian or Alaska Native
o 2=Asian
o 3=Black or African American
o 4=Native Hawaiian or Other Pacific Islander
o 5=Caucasian
Advanced directive (0=None, 1=DNI, 2=DNR, 3=Other)
ICU discharge date and time
ICU discharge status (1=Alive, 2=Dead)
Hospital discharge status (1=Alive, 2=Dead)
Corticosteroid use: (1 = Yes, 0 = No)
Total vasopressor dose (MG) NE
Total vasopressor dose (MG) VP
Total vasopressor dose (MG) EPI
Total vasopressor dose (MG) PH
Total vasopressor time (HR)
Temp (F)
RR
HR
MAP
Fio2
Pa02
ADO2
HCT
WBCs
pH
Na
K
Creatinine
Hco3
platelets
bilirubin
GCS
Intubated (1 = Yes, 2 = No)
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Degree of hypotension
o 0=none
o 1=MAP < 70 mmHg
o 2=Dopamine ≤ 5mcg/kg/min
o 3=Dopamine > 5mcg/kg/min; Dobutamine > 5mcg/kg/min;
Epinephrine ≤ 0.1 mcg/kg/min; Norepinephrine ≤ 0.1 mcg/kg/min
o 4=Dopamine > 15mcg/kg/min; Dobutamine > 15 mcg/kg/min;
Epinephrine > 0.1 mcg/kg/min; Norepinephrine> 0.1 mcg/kg/min;
Vasopressin (any dose)
P/F Ratio
APACHE
SOFA
Primary diagnosis
o (1) Nervous System
o (2) Integumentary
o (3) Cardiovascular
o (4) Pulmonary
o (5) Gastrointestinal
o (6) Genitourinary
o (7) Other
Infectious diagnosis
o (1) Nervous System
o (2) Integumentary
o (3) Cardiovascular
o (4) Pulmonary
o (5) Gastrointestinal
o (6) Genitourinary
o (7) Other
Positive culture at discharge/death (0=no, 1=yes)
Art line (0=no, 1=yes)
Correct Nurse Titration
Failure to Titrate
Incorrect Downward Titration
Incorrect Upward Titration
notes
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Acute Physiology and Chronic Health Evaluation II [APACHE II] Scoring
Score

+4

Rectal temp (C)

>41

Mean arterial
pressure
(mmHg)
Heart rate
(beats per
minute)
Respiratory rate
(breaths per
minute)
Oxygenation
If intubated and
FIO2 ≥ 0.50, use
AaDO2*
If intubated and
FIO2 < 0.50, use
PaO2
Arterial pH
Serum sodium
(mmol/l)
Serum
potassium
(mmol/l)
Serum
creatinine
(mg/dl)
(Double score
for acute renal
failure)
Hematocrit (%)

+3
+2
3940.9

+1
0
+1
+2
38.5- 36- 34- 3238.9 38.4 35.9 33.9

+3
3031.9

+4
<29.9

>160

130- 110159 129

70109

50-69

>180

140- 110179 139

70109

55-69 40-54 <39

>50

3549

>500

1224

1011

350- 200499 349

<
200
>70

6170

7.67.57.69
7.59
160- 155- 150>180
179 159 154

7.37.49
130149

5.55.9

3.55.4

25-34

>7.7

>7

6-6.9

>3.5

2-3.4

>60

1.51.9
5059.9
2039.9

0.61.4
4649.9
1519.9

3045.9
314.9

6-9

<5

55-60 <50
7.257.3
120129

33.4

<49

2.52.9

7.15- <
7.24 7.15
111<110
119
<2.5

<0.6

2029.9

< 20

White cell count
>40
1-2.9
<1
(103/ml)
Glascow Coma
Score = 15 minus actual GCS ________________
Score(GCS)
Serum HCO3
4132221815(mmol/L) (only ≥ 52
< 15
51.9
40.9 31.9
21.9 17.9
if no ABG)
Note. FIO2= Fraction of Inspired Oxygen; AaDO2=Alveolar–Arterial gradient;
PaO2=Partial pressure of oxygen in arterial blood; HCO3= bicarbonate;
ABG=Arterial Blood Gas
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Sequential Organ Failure Assessment Scoring
Score
PaO2/FIO2
(mmHg)
Platelets
(103/L)
Bilirubin
(mg/dL)

0
>
400
>
150
<
1.2

1

2

3

4

≤ 400

≤ 300

≤ 200

≤ 100

≤ 150

≤ 100

≤ 50

≤ 20

1.21.9

2.0-5.9

6.0-11.9

> 12

Dopamine >
5mcg/kg/min
Dobutamine
>
5mcg/kg/min
Hypotension

Non
e

MAP
< 70
mmH
g

Dobutamine >
15 mcg/kg/min

Dopamine
Epinephrine >
Epinephrine ≤
≤
0.1
0.1
5mcg/kg/mi
mcg/kg/min
mcg/kg/min
n
Norepinephrin
Norepinephri
e> 0.1
ne ≤ 0.1
mcg/kg/min
mcg/kg/min
Phenylephrin
e (any dose)

Glascow Coma
Score (GCS)
Creatinine(mg/d
L)

Dopamine >
15mcg/kg/min

Vasopressin
(any dose)

15

13-14

10-12

6-9

<6

<
1.2

1.21.9

2.0-3.4

3.5-4.9

>5

Note. PaO2=Partial pressure of oxygen in arterial blood; FIO2= Fraction of
inspired oxygen
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DATA GUIDEBOOK AND DEFINITIONS
Study ID Number
•The study ID number will be a 3-digit number starting with either “C” for
control or “E” for experimental. Each category will start with 001 and
continue numerically until data collection is complete in that category to a
maximum of 999 in each category.
Bed Number
•The location in the Medical Intensive Care Unit (MICU) the patient was
located upon study recruitment.
Medical Record Number
•9-digit Methodist Hospital System number
Age
•Age in years upon admission into the study
Gender
• (1=Male, 2=Female, 3=other)
Hospital admission date and time.
•Hospital admission date and time. This is an admission event noted after
the provider enters a hospital Admit Discharge Transfer (ADT) order. This
does not include the time the patient is admitted for observation status.
The time will be documented in military time format.
ICU admit date and time
•ICU admission date and time for the first MICU admission during study
enrollment. The time will be documented in military time format.
Ethnicity:
•1 = Not-Hispanic/Latino, 2 = Hispanic/Latino
Race:
•1=American Indian or Alaska Native
•2=Asian
•3=Black or African American
•4=Native Hawaiian or Other Pacific Islander
•5=Caucasian
Advanced Directive
• (0=None, 1=DNI, 2=DNR, 3=Other)
•Any advanced directive entered during the first MICU admission of study
enrollment.
ICU Discharge Date and time
•ICU discharge date and time for the first MICU discharge during study
enrollment. The time will be documented in military time format.
ICU Discharge Status
•1 = alive, 2 = deceased
Hospital Discharge Date
•Hospital discharge date and time. The time will be documented in military
time format.
Hospital Discharge Status
•1 = alive, 2 = deceased
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Corticosteroid use: 1 = Yes, 2 = No
•Any use of hydrocortisone in doses of 200-300mg per day per Surviving
Sepsis Guidelines for ≥ 24 hours. Intermittent steroid use will not be
measured or calculated.
MICU bed number
•The MICU bed number will be listed as a numerical variable ranging from
1-24.
Total vasopressor dose (mg and units)
•Norepinephrine, phenylephrine, and epinephrine will be measured in mg.
Vasopressin will be measured in total units.
•The total vasopressor dose will be calculated based on volume
administered after initiation. This will include vasopressors administered in
the emergency room and non-ICU settings (excluding the operating room).
Once vasopressors are stopped for more than 4 hours, this data will be
collected and the patient will be excluded from an additional enrollment
into the study.
•Caution should be taken to incorporate the concentration of the
medication in each bag during the calculation. Dose will be displayed in
milligrams on the data collection sheet.
Total vasopressor time (hours)
•The total vasopressor time will be calculated based on manual data
collection from the flow sheet section of the EHR. Inclusion criteria
dictates that patients will be included if receiving vasopressors for more
than 4 hours. Data collection will start from the commencement of
vasopressors (inclusive of the 4 hours) and end when the patient does not
receive vasopressors for more than 4 hours.
Primary diagnosis
• (1) Nervous System
• (2) Integumentary
• (3) Cardiovascular
• (4) Pulmonary
• (5) Gastrointestinal
• (6) Genitourinary
• (7) Other
•Infectious diagnosis
• (1) Nervous System
• (2) Integumentary
• (3) Cardiovascular
• (4) Pulmonary
• (5) Gastrointestinal
• (6) Genitourinary
• (7) Other
Positive cultures at discharge/death
• (1 = Yes, 0 = No) Any culture to include but not limited to blood, CSF,
sputum, or any other bodily fluid.
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Arterial Catheter
• (1 = Yes, 0 = No). Presence of arterial catheter during the first MICU
admission during study enrollment.
Nurse Titration Data:
Correct Nurse Titration
•The total number of times the nurse properly titrated vasopressors per the
recorded vital sign data in the EHR
Failure to Titrate
•The total number of times the nurse did not titrate vasopressors per the
recorded vital sign data in the EHR
Incorrect Downward Titration
•The total number of times the nurse decreased the vasopressor dose
without a recorded vital sign data to support downward titration
Incorrect Upward Titration
•The total number of times the nurse increased the vasopressor dose
without a recorded vital sign data to support upward titration
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APACHE II scores will be calculated using the following calculator:
ClinCalc. (2019). Acute Physiology and Chronic Health Evaluation (APACHE) II
Calculator. Retrieved from: https://clincalc.com/IcuMortality/APACHEII.aspx
GENERAL INSTRUCTIONS


To calculate the Total APACHE score, sum the 3 following domains:
A. PHYSIOLOGIC VARIABLES (APS) (total of 12 variables)
There will be 11 variables if there is no ABG available as the oxygenation
and Arterial pH variable are not summated, however, you will be using the
Serum HCO3 variable
B. AGE POINTS
C. CHRONIC HEALTH POINTS

A) PHYSIOLOGIC VARIABLES







All APACHE II data collected must be from the first 24 hours following ICU
admission. The GCS assessment should be taken prior to the patient
receiving sedation. This may be outside of the 24-hour assessment period but
will provide a more accurate score of neurological function.
For all acute physiologic measurements: choose the worst, most abnormal
value recorded during the full 24-hour assessment period. These values may
be low or high, but will always be the most deranged value with the highest
point score.
Values from the operating room will not be included.
Transient obviously erroneous values will not be collected (eg. Heart rate of
zero with a documented blood pressure).
The 12 Physiological Variables are:

1.
2.
3.
4.

Temperature
Rectal or core temperature in degrees Fahrenheit (°F) preferred.
Mean Arterial Pressure (MAP)
Record in mmHg
Use the following formula to calculate the MAP: SBP +[DBP×2]÷3
Arterial line MAP is preferred over NIBP measures
Heart Rate
Do not score for bradycardia if a pacemaker is present.
Record the documented ventricular rate.
Respiratory Rate
- Record the most deranged ventilated or non-ventilated rate.
5. Oxygenation
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If the patient has an FiO2 < 0.5 AND > 0.5 within this same 24-hour period,
use the AaD02 or Pa02/Fi02 value which scores highest in this category.
The formula to calculate AaD02 at sea level is: [FiO2 ×713]-[PaCO2÷0.8]PaO2
At sea level (an altitude less than 1000 feet) use a barometric pressure of 760
mmHg minus the pressure of water (47 mmHg) for a total pressure of 713
mmHg.
If a patient with an FiO2<0.5 AND no Pa02. It is acceptable to use SPO2 in
the place of Pa02

6. Arterial or venous pH
- The worst, most abnormal value preferably recorded during the full 24-hour
assessment period. However, variables collected within 48 hours are
acceptable if none are available within 24 hours of ICU admission
7. Serum Sodium (mEql/L)
8. Serum Potassium (mEql/L)
9. Serum Creatinine (mg/dL)
- Patients score double points for ACUTE renal failure.
10. Hematocrit (%)
11. White Blood Cell Count (K/uL)
12. Glasgow Coma Scale (GCS)
- Calculate the GCS by assessing each of the three components: eye opening,
motor response, and verbal response.
- Choose the most accurate, lowest cumulative score available in the 24- hour
assessment period.
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If a patient has received sedation or paralytic agents, it is preferable to record
the GCS prior to receiving the medications even if outside the 24- hour
assessment period.
Patients who receive large amounts of sedation may have their GCS
recorded as “3” (i.e. no response for eye opening, motor, or verbal).
For intubated patients use your best clinical judgment when scoring “verbal
response” or score 10T.
Enter the total score of the GCS based on the following definition:

Eye Opening Response
Spontaneous = 4
To Voice
= 3
To Pain
= 2
None
= 1

Motor Response
Obeys Commands =
Localizes to Pain =
Flexion / Withdrawal =
Abnormal Flexion
=
Extension
=
No Response
=

6
5
4
3
2
1

Verbal Response
If not intubated:
Oriented
= 5
Confused
= 4
Inappropriate
= 3
Incomprehensible = 2
No Response
= 1
If intubated:
= 0

13. Serum HCO3 (venous mEql/L) - not preferred, use if no ABG's
B) AGE POINTS
Appropriately assign Age Points as follows. Remember to carefully calculate
the patient’s age.
Age (years)
< 44
45-54
55-64
65-74
> 75

Points
0
2
3
5
6

C) CHRONIC HEALTH POINTS


Appropriately assign Chronic Health Points using the definitions listed below.
If a patient has evidence of one or more of the following criteria (1-5), points
will be scored as follows:
a) Non-operative or emergency postoperative patients = 5 points
b) Elective postoperative patients = 2 points
c) If the patient has no chronic health states = 0 points
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“Emergency postoperative patient” will be defined as a patient who has
received surgery required immediately to correct a life-threatening condition.
A total of either “0”, “2”, or “5” points can be scored for this section. Points are
not calculated based on the number of chronic health conditions.
The patient’s complete medical history / hospital chart should be reviewed for
assessment of this category.
Organ insufficiency or immunocompromised state must have been evident
prior to this hospital admission and conform to the following definitions:

1) LIVER
Biopsy proven cirrhosis and documented portal hypertension, episodes of
past upper GI bleeding attributed to portal hypertension or prior episodes of
hepatic failure/encephalopathy/coma.
2) CARDIOVASCULAR
New York Heart Class IV. Dyspnea at rest (patients who should be at
complete rest, confined to bed or chair; any physical activity brings on
discomfort and symptoms occur at rest).
3) RESPIRATORY
Chronic restrictive obstructive vascular disease resulting in severe exercise
restriction, i.e. unable to climb stairs or perform household duties or
documented chronic hypoxia, hypercapnia, secondary polycythemia, severe
pulmonary hypertension (>40mmHg) or respiratory dependency.
4) RENAL
Receiving chronic dialysis.
5) IMMUNOCOMPROMISED
The patient has received therapy that suppresses resistance to infection, (e.g.
immuno-suppression, chemotherapy, radiation, long term or recent high dose
steroids) or has a disease that is sufficiently advanced to suppress resistance
to infection, (e.g. leukemia, lymphoma, multiple myeloma, AIDS).
The definition for long term high dose steroids is:
a) Greater than 0.3 mcg/kg/day of Prednisone or its equivalent daily for 6
months.
b) Use of active radio- or chemotherapy in the previous year.
REFERENCES AND RESOURCES
1) Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A
severity of disease classification system. Crit Care Med 1985; 13(10):818-829
2) Livingston BM, Mackenzie SJ, MacKirdy FN, Howie JC. Should the
presedation Glasgow Coma Scale value be used when calculating Acute
Physiology and Chronic Health Evaluation scores for sedated patients? Crit
Care Med 2000; 28(2):389-394
3) Medical Information Eli Lilly Canada Inc. Use of APACHE II in the
PROWESS Trial.
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ADAPTED FROM:
Cook, Deborah J., et al. "Probiotics: Prevention of Severe Pneumonia and
Endotracheal Colonization Trial—PROSPECT: a pilot trial." Trials 17.1
(2016): 377.
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Sequential Organ Failure Assessment (SOFA) Score
SOFA scores will be calculated using the following calculator:
MDCalc. (2018). Sequential Organ Failure Assessment (SOFA) Score
Calculator. Retrieved from: https://www.mdcalc.com/sequential-organ-failureassessment-sofa-score
RESPIRATION:
 Intubated:
 1 = Yes, 2 = No. Intubated includes any patient with an artificial airway in
the trachea EXCLUDING procedures within the first 24 hours of ICU
admission. This includes but is not limited to oral tracheal intubation, naso
tracheal intubation, and a tracheostomy.
 PaO2
 The worst, most abnormal value within the 24 hour collection period
 If the patient does not have a recorded Pa02, it is acceptable to use
Spo2/Fio2 ratio to impute for Pao2/Fio2 ratio in the respiratory component
of the Sequential Organ Failure Assessment score (Pandharipande, et. al,
2009)
 Fio2
 Fraction of inspired oxygen collected with Pa02 measurement
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COAGULATION:
 Platelets
 Defined as the worst, most abnormal value recorded during the full 24hour assessment period. Measured in k/uL.
LIVER:
 Total Bilirubin
 The worst, most abnormal value preferably recorded during the full 24hour assessment period. However, variables collected within 48 hours are
acceptable if none are available within 24 hours of ICU admission.
Measured in mg/dL.
CARDIOVASCULAR:
 Severity of Hypotension
 0=none
 1=MAP < 70 mmHg
 2=Dopamine ≤ 5mcg/kg/min
 3=Dopamine > 5mcg/kg/min; Dobutamine > 5mcg/kg/min; Epinephrine ≤
0.1 mcg/kg/min; Norepinephrine ≤ 0.1 mcg/kg/min
 4=Dopamine > 15mcg/kg/min; Dobutamine > 15 mcg/kg/min;
Epinephrine > 0.1 mcg/kg/min; Norepinephrine> 0.1 mcg/kg/min;
Vasopressin (any dose)
 Admission weight will be utilized for kg/min calculations.
CENTRAL NERVOUS SYSTEM
 Glasgow Coma Scale (GCS)
 Calculate the GCS by assessing each of the three components:
eye opening, motor response, and verbal response.
 Choose the most accurate, lowest cumulative score available in the
24-hour assessment period.
 If a patient has received sedation or paralytic agents, it is preferable
to record the GCS prior to receiving the medications even if outside
the 24-hour assessment period.
 Patients who receive large amounts of sedation may have their
GCS recorded as “3” (i.e. no response for eye opening, motor, or
verbal).
 For intubated patients use your best clinical judgment when scoring
“verbal response” or score 10T.
RENAL
 Serum Creatinine (preferred)
 Defined as the worst, most abnormal value recorded during the full 24hour assessment period. Measured in k/uL (mg/dL)
Adapted From:
Pandharipande, P. P., Shintani, A. K., Hagerman, H. E., St Jacques, P. J., Rice, T. W., Sanders,
N. W., ... & Ely, E. W. (2009). Derivation and validation of SpO2/FiO2 ratio to impute for
PaO2/FiO2 ratio in the respiratory component of the Sequential Organ Failure Assessment
(SOFA) Score. Critical care medicine, 37(4), 13171).
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NARROWED MONITOR ALARM PARAMETERS TO DECREASE VASOPRESSOR USAGE
IN SEPTIC SHOCK: AN HISTORICAL CONTROL INTERVENTION STUDY
RECRUITMENT SCREENING TOOL
The sample will be adult ICU patients with septic shock, defined as the presence of an
infection, with end organ dysfunction and hemodynamic compromise, and on vasopressor
therapy.

Inclusion Criteria:

Exclusion criteria:

☐

☐

☐

MICU patient ≥ 18 years old

cardiogenic, obstructive, or
neurogenic)
Septic Shock with

☐

administration of vasopressor
therapy for ≥ 4 hours to maintain
MAP > 60 mmHg

☐

Other types of shock (i.e.,

Inability to determine

presence of infectious process

☐

Central Venous Catheter

Pregnancy

☐
☐

Septic Shock Criteria

Infection Criteria
(At least 1)
1) Leukocytes in otherwise
sterile corporal liquid
2) Radiographic evidence of
pneumonia
3) Perforated abdominal
viscus
4) Clinical syndrome
associated with infection
(e.g., cholangitis)

Severe head injury

Post cardiac arrest

Sepsis
Suspected
infection

Septic Shock
Sepsis
+

+
Vasopressors
≥2 qSOFA score
+
OR
Lactate >2mmol/L
≥2 rise in Overall
SOFA score

qSOFA
1) Altered Mental Status
2) RR≥22
3) SBP≤100
Note: RR=Respiratory Rate; qSOFA=quick Sepsis Related Organ Failure
Assessment SBP=Systolic Blood Pressure; SOFA=Sepsis Related Organ
Failure Assessment
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APPENDIX C
MANUSCRIPT
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